Navigation Links
Newly discovered regulatory mechanism essential for embryo development and may contribute to cancer
Date:10/28/2010

Researchers from Mount Sinai School of Medicine have identified a mechanism controlling the function of a protein that binds to DNA during embryonic development and may function to prevent abnormal tumor growth. When the protein, TCF3, is modified by a small molecule called a phosphate, it no longer binds DNA, changing the way the protein signals during development. This discovery identifies a new diagnostic marker (phosphorylated TCF3) that may be associated with cancer and could represent a potential drug target. The results are published in the current issue of Developmental Cell.

Led by Sergei Sokol, PhD, Professor of Developmental and Regenerative Biology at Mount Sinai School of Medicine, the research team analyzed frog embryos to get a better understanding of how cells "talk" to each other and differentiate into various cell types, e.g., neurons or muscle cells. One such way these cells communicate is through signaling proteins called Wnts, which function during embryonic development and malfunction in cancer, including colon carcinomas, melanomas, skin, lung and liver tumors. Dr. Sokol's team analyzed what happens when a cell responds to Wnt protein..

The researchers' results suggest that Wnt signal activates a special enzyme, called homeodomain-interacting protein kinase that adds a phosphate group to TCF3. This event changes the activity of TCF3 and activates gene expression during early development, allowing embryonic tissues to develop tail structures. Although essential in the early embryo, the same process can cause tumor formation in the adult.

"Our study is the first to show an alternative mechanism of Wnt signaling, that operates in vivo to modulate the activity of TCF3," said Dr. Sokol. "We now know that this change in TCF3 activity leads to a profound alteration of target genes that are important in early development and are abnormally regulated in cancer."

These data potentially provide a diagnostic or therapeutic target in identifying and treating common types of cancer. If the presence of the phosphate molecule on TCF3 is identified, then the cancer may be caught earlier, providing more treatment options. Additionally, knowing that this modification of TCF3 may cause abnormal cell growth would allow researchers to develop drugs that can inhibit its action.

"While more research is needed, our study is a promising first step toward earlier diagnosis and better treatment for many common cancers," said Dr. Sokol. "We look forward to gaining further understanding of the role of TCF regulation for gene expression."


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Beat The Odds and Get Back on Track; Revitalizing Fitness Training and Exercise Resolutions With Newly Released, Complimentary Video Series
2. Gene discovered for newly recognized disease in Amish children
3. Newly identified proteins critical to FA pathway DNA repair function
4. Khanna Institute to Offer Newly FDA Approved Expanded Range of Intacs for Keratoconus
5. ProbioticSmart.com Re-Launches Newly Expanded Online Store for Human, Pet, and Livestock Health Products and Supplements
6. Newly Relaunched Autoinsurance.net Offers Consumers Smart Tips To Consider When Purchasing Car Insurance
7. Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book”
8. Caregivers Find Hearing Loss Newly Relaunched Website a Welcome Help
9. Altered brain development found in children with newly diagnosed epilepsy
10. Color-coded tracking method helps scientists analyze outcomes of newly transplanted tissue
11. Liberty Health shows how the BP Oil Spill may draw attention to the purity of the company's newly released Nutritional Supplements.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... CA (PRWEB) , ... December 07, 2016 , ... ... provides insurance and financial consultation services to residents in the Sacramento/Folsom region, is ... Another Chance treatment facility. , The Another Choice Another Chance treatment center in ...
(Date:12/7/2016)... ... OCTOBER XX, 2016 (PRWEB) (PRWEB) December 07, 2016 ... ... A new study entitled “Canine Filamentous Dermatitis Associated with Borrelia Infection” ... dogs. The study was published in the prestigious Journal of Veterinary Science & ...
(Date:12/7/2016)... Dallas, TX (PRWEB) , ... December 07, 2016 ... ... service based in Dallas, Texas, is condemning "scam operations" carried out by unethical ... to bring these scam operations to a halt. According to Texas Premier Locksmith, ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers and ... substantially enhances the WellnessPro platform by expanding the treatment modalities available in ...
(Date:12/7/2016)... ... December 07, 2016 , ... “Fred Rides a Train” allows readers ... follows. , “Fred Rides a Train” is the creation of published author, Janet ... her teen years in Michigan. The "Fred, the Dog" series is her first attempt ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   Rx Savings Solutions ... and its Public Employees Insurance Agency (PEIA) to ... to their innovative healthcare software, ultimately saving money on their ... and provide its members with access to our software that ... more effective, affordable therapy can be found," says Michael ...
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems ... to its previously announced plans to separate its Imaging ... via a tax-free distribution to Varian stockholders of common ... company that will hold the Imaging Components business.  As ... be executed by the end of January 2017, Varian ...
(Date:12/7/2016)... 7,2016  Based on its recent analysis ... & Sullivan recognizes Nemaura Pharma Limited with ... for Enabling Technology Leadership. Nemaura Pharma,s transdermal ... traditional drug delivery technologies, especially in delivering ... delivery technologies, Memspatch and Micropatch respectively, facilitate ...
Breaking Medicine Technology: